Shots:

• The approval is based on P-III trial Fixed Combination Drug Product LDL-C Lowering program- involves assessing of Nexlizet vs PBO when added on to maximally tolerated statins
• The study resulted in well-tolerated data and lowered LDL-C by 38%- when added on to maximally tolerated statins. Also- the results are published in The European Journal of Preventative Cardiology
• Nexlizet is an oral qd- non-statin LDL-cholesterol lowering medicine approved by the US FDA on Feb 21- 2020 and will be available in Jul- 2020. Nexletol (bempedoic acid) is a novel ATP Citrate Lyase inhibitor involves lowering of LDL-C by cholesterol biosynthesis and up-regulating the LDL receptors- will be available from Mar 30- 2020

Click here to read full press release/ article | Ref: GlobNewswire | Image: Signbox